Nilotinib by LC-MS/MS
Clinical details: 
Nilotinib (Tasigna, Novartis) is a second-generation tyrosine kinase inhibitor (TKI), and is used in the treatment of chronic myeloid leukaemia (CML). It is used in patients who have primary resistance to imatinib, which may occur in 15-20 % of cases. Treatment failure has been attributed to poor adherence or inadequate dosage. Thus, monitoring plasma nilotinib may help in assessing adherence and in optimising treatment. A target range for plasma nilotinib during effective therapy has not been established as yet. However, in patients prescribed nilotinib for CML (400 mg twice daily, 15 d) the mean (SD) pre-dose plasma nilotinib concentration was 1.0 (+/- 0.5) mg/L.
Sample type and Volume required: 
2mL EDTA whole blood or 1 mL plasma or serum (pre-dose or ‘trough’ sample).
Turnaround time: 
5 working days
Storage and transport: 
Please refrigerate (if possible) if not sending immediately. Send by first class post.
Toxicology Department at King's Hospital
020 3299 5881
King's College Hospital
Bessemer Wing - 3rd Floor
Denmark Hill
London SE5 9RS
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 07/08/2015